The ATM kinase inhibitor, KU-60019, preferentially sensitizes PTEN-deficient MDA-MB-468 breast cancer cells to cisplatin, while only slightly enhancing sensitivity of PTEN-wild type breast cancer cells [187]. Here, PTEN is linked to breast carcinoma.